Witt, S., Schuett, K., Wiegand-Grefe, S., Boettcher, J
At baseline (1 October 202231 November 1, 2023), several clinical and demographic factors were examined
A $150 savings was too good to pass up
Comparing Effectiveness: What the Research Shows Weight Loss Results The SURMOUNT-1 clinical trial comparing tirzepatide directly to a placebo showed remarkable results: Tirzepatide 5mg: Average 15% weight loss Tirzepatide 10mg: Average 19.5% weight loss Tirzepatide 15mg: Average 20.9% weight loss Compare this to semaglutides STEP trials: Semaglutide 2.4mg: Average 14.9% weight loss While both medications produce significant results, tirzepatide shows a statistical advantage, particularly at higher doses
Retatrutide will now advance to Phase 3 clinical trials that will gather evidence supporting the drug's approval in the United States